A prospective observational study of problematic oral cannabinoid use
- 561 Downloads
Despite evidence supporting the benefits of cannabinoids for symptom control across a wide range of medical conditions, concerns have been raised regarding the potential misuse and/or problematic use of cannabinoids (CBs).
The first objective of this study was to examine the incidence of problematic prescription cannabinoid use (PPCBU) over a 12-month period among patients initiating cannabinoid therapy. The second objective was to examine the factors associated with PPCBU. A total of 265 patients who were prescribed oral cannabinoid therapy as part of usual medical practice were enrolled into this prospective observational study. Patients first completed a series of baseline questionnaires assessing demographic, clinical, and substance use variables. Three measures designed to assess PPCBU were then administered at 3, 6, and 12 months after initiation of cannabinoid therapy.
At each of the follow-up assessment time points, a significantly greater number of patients scored below (vs above) cutoff scores on the three main PPCBU outcomes (all p’s < .001). At any follow-up time point, a maximum of roughly 25% of patients demonstrated PPCBU. Heightened odds of PPCBU were observed among patients with a history of psychiatric problems, tobacco smokers, and recreational cannabis users (all p’s < .05). Results indicated that past-year substance abuse, assessed using the DAST-20, was the strongest predictor of PPCBU (p < .005).
Findings from the present study could have implications for clinicians considering the use of cannabinoids for the management of patients with medical conditions. Although results indicated that the majority of patients included in this study did not reach cutoff scores on the three main PPCBU outcomes, our findings suggest that PPCBU should be routinely assessed and monitored over the course of cannabinoid therapy, particularly among patients with a history of psychiatric or substance use problems.
KeywordsCannabinoids Problematic cannabinoid use Incidence Risk factors
The authors wish to acknowledge all the additional clinical site investigators who enrolled subjects for the study, including Dr. Gordon Ko, Dr. Peter Blecher, Dr. Aline Boulanger, and Dr. May Ong-Lam. We also wish to acknowledge the advice of Dr. Kenneth Kirsch, the study management team at AXON for study coordination and data management, and medical writer Mark E. Rose, MA, for putting together the early draft of the paper.
The study was supported by an unrestricted educational grant from Valeant Pharmaceuticals (Canada). Valeant markets nabilone under the brand name Cesamet®.
Compliance with ethical standards
Conflict of interest
MAW discloses the following relationships: CanniMed, Green Sky Labs (grant to institution), CHI Inc., Zynerba, and CannaRoyalty (consultant). RJ discloses the following relationships: Astra Zeneca, Knight, Paladin, and Purdue Pharma (speakers’ bureau, consultant). MM and JS declare that they have no conflict of interest.
- Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7):515–521. https://doi.org/10.1212/01.wnl.0000253187.66183.9c CrossRefPubMedGoogle Scholar
- Carliner H, Brown QL, Sarvet AL, Hasin DS (2017) Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. https://doi.org/10.1016/j.ypmed.2017.07.008
- Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10(2):113–130. https://doi.org/10.1016/j.jpain.2008.10.008 CrossRefPubMedPubMedCentralGoogle Scholar
- Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O’Leary C, Ratcliffe S, Novakova I, Zapletalova O, Pikova J, Ambler Z (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32(5):451–459. https://doi.org/10.1179/016164109X12590518685660 CrossRefPubMedGoogle Scholar
- Guy W (1976) Assessment manual for psychopharmacology—revised. Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, pp 218–222Google Scholar
- Hasin DS (2017) US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology 43(1):195-212Google Scholar
- Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 72(12):1235–1242. https://doi.org/10.1001/jamapsychiatry.2015.1858 CrossRefPubMedPubMedCentralGoogle Scholar
- Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF (2016) Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry 173(6):588–599. https://doi.org/10.1176/appi.ajp.2015.15070907 CrossRefPubMedPubMedCentralGoogle Scholar
- Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilliday BB, DeWalt DA, Pignone MP (2006) Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 6(1):46. https://doi.org/10.1186/1472-6963-6-46 CrossRefPubMedPubMedCentralGoogle Scholar
- Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 39(2):167–179. https://doi.org/10.1016/j.jpainsymman.2009.06.008 CrossRefGoogle Scholar
- Liebschutz JM, Saitz R, Weiss RD, Averbuch T, Schwartz S, Meltzer EC, Claggett-Borne E, Cabral H, Samet JH (2010) Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 11(11):1047–1055. https://doi.org/10.1016/j.jpain.2009.10.012 CrossRefPubMedPubMedCentralGoogle Scholar
- Martel MO, Finan PH, McHugh RK, Issa M, Edwards RR, Jamison RN, Wasan AD (2016) Day-to-day pain symptoms are only weakly associated with opioid craving among patients with chronic pain prescribed opioid therapy. Drug Alcohol Depend 162:130–136. https://doi.org/10.1016/j.drugalcdep.2016.02.047 CrossRefPubMedPubMedCentralGoogle Scholar
- Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN (2004) Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manag 28(3):250–258. https://doi.org/10.1016/j.jpainsymman.2004.04.007 CrossRefGoogle Scholar
- Nielsen S, Lintzeris N, Bruno R, Campbell G, Larance B, Hall W, Hoban B, Cohen ML, Degenhardt L (2015) Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. Pain Med (Malden, Mass) 16(2):356–366. https://doi.org/10.1111/pme.12594 CrossRefGoogle Scholar
- Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler (Houndmills, Basingstoke, England) 18(2):219–228. https://doi.org/10.1177/1352458511419700 CrossRefGoogle Scholar
- Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449. https://doi.org/10.1016/j.jpain.2012.01.003 CrossRefPubMedGoogle Scholar
- Saunders KW, Von Korff M, Campbell CI, Banta-Green CJ, Sullivan MD, Merrill JO, Weisner C (2012) Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors. J Pain 13(3):266–275. https://doi.org/10.1016/j.jpain.2011.11.004 CrossRefPubMedPubMedCentralGoogle Scholar
- Savage SR (2008) The language of pain and addiction. In: Smith HS, Passik SD (eds) Pain and chemical dependency. Oxford, pp 9–13Google Scholar
- Smith HS, Passik SD (2008) Pain and chemical dependency. Oxford University Press, New YorkGoogle Scholar
- Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, Garven A, Bestard J, Korngut L (2012) An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 153(10):2073–2082. https://doi.org/10.1016/j.pain.2012.06.024 CrossRefPubMedGoogle Scholar
- Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler (Houndmills, Basingstoke, England) 10(4):434–441. https://doi.org/10.1191/1352458504ms1082oa CrossRefGoogle Scholar
- Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN (2007) Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 23(4):307–315. https://doi.org/10.1097/AJP.0b013e3180330dc5 CrossRefPubMedGoogle Scholar